Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Exosome-based cancer Dx attracts $20m investment

This article was originally published in Clinica

Executive Summary

Exosome Diagnostics has raised $20m in its first institutional financing round. Co-lead investors were NGN Capital and Forbion Capital Partners. Exosome, which is based in New York and Munich, said it will use the funds to further develop and commercialise a series of body fluid-based cancer diagnostics through its proprietary, exosome-based technology platform. Exosomes are lipid-covered microvesicles shed by solid tumours into bodily fluids, such as blood and urine. These microvesicles contain large sequences of a tumour’s genetic material in an enriched form. The company has demonstrated that it is able to extract high-quality exosomes from the blood and urine of cancer patients; and then detect, with high sensitivity and specificity, key genes and gene mutations associated with a variety of cancers.

You may also be interested in...

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts